ANGULO

Humanigen’s Budget Impact Model Demonstrates Lenzilumab’s Potential Positive Economic Value in Hospitalized COVID-19 Patients

Retrieved on: 
월요일, 10월 11, 2021

These results highlight the value of selecting the right treatment for the right hospitalized patients during this time of unprecedented pressure on health systems.

Key Points: 
  • These results highlight the value of selecting the right treatment for the right hospitalized patients during this time of unprecedented pressure on health systems.
  • Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), is a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm.
  • Humanigens Phase 3 LIVE-AIR study suggests early intervention with lenzilumab may prevent consequences of a full-blown cytokine storm in hospitalized patients with COVID-19.
  • Health Outcomes and economic burden of hospitalized COVID-19 patients in the United States.